ClinicalTrials.gg
CompletedNCT04944992Updated Nov 15, 2023Results posted

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

A Phase 2 interventional study of Efinopegdutide 20 mg/mL and Semaglutide 1.34 mg/mL in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, sponsored by Merck Sharp & Dohme LLC. Completed at 69 sites in 16 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.

Enrollment
4th of 10
145 · median 113
Started
2021
with 1 other
Phase 2
7 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 6th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc as a file.
02

Study summary

The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.

03

Conditions studied

  • Nonalcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • LFC ≥10% as assessed by MRI-PDFF at time of screening.
  • (BMI) ≥25 kg/m² and ≤50 kg/m² at time of screening.
  • Stable weight (based on self-reporting) defined as ≤5% gain or loss of body weight for at least 3 months before screening visit.
  • No history of Type 2 Diabetes Mellitus (T2DM) OR history of T2DM with an (A1C) ≤8.5% at screening AND controlled by diet or a stable dose of metformin for the 3 months before screening.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of (WOCBP), or is a WOCBP and agrees to follow guidance during the study intervention period and for at least 5 weeks after the last dose of study intervention.
  • Participants in Taiwan are eligible between the ages of 20 to 70 years of age (inclusive).
  • Participants in South Korea are eligible between the ages of 19 to 70 years of age (inclusive).

Exclusion criteria

Exclusion Criteria:

  • History of Type 1 Diabetes Mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatitis or pancreatectomy.
  • Ongoing, inadequately controlled hypothyroidism or hyperthyroidism.
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasm type-2 syndrome.
  • Recent event (within 6 months prior to screening) of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or .
  • History or evidence of chronic liver disease other than NAFLD or Non-Alcoholic SteatoHepatitis (NASH).
  • Known history of cirrhosis.
  • History of acute or chronic pancreatitis.
  • History of a bariatric surgical procedure or a known gastric emptying abnormality.
  • History of ≤5 years prior to screening, except for skin cancer or cervical cancer.
  • Clinically active hematologic disorder.
  • Diagnosis of (HIV).
  • Surgery requiring general anesthesia within 3 months before screening visit.
  • History of organ transplantation, except for corneal transplant.
  • Active diabetic proliferative retinopathy or a history of maculopathy.
  • Untreated obstructive sleep apnea.
  • History of treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist within 6 months before screening.
  • History of treatment with thiazolidinediones (ie, pioglitazone, rosiglitazone) within 6 months before screening.
  • Previous use (within 3 months before screening) or current use of prescription weight-management medications or over-the-counter weight-loss medications or therapies.
  • Treatment with systemic medication within 3 months before screening.
  • Current treatment with anticoagulants (eg, warfarin, heparin).
  • Inability to have an MRI-PDFF performed due to either severe claustrophobia, metallic implant that prevents MRI-PDFF examination, or any other to MRI-PDFF examination.
  • Previous or current history of significant alcohol consumption (average of 7 standard drinks per week in females or 14 standard drinks per week in males) for a period of more than 3 consecutive months in the 24 months before screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Efinopegdutide

    Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.

    Drug: Efinopegdutide 20 mg/mL

  • Active comparator
    Semaglutide

    Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.

    Drug: Semaglutide 1.34 mg/mL

Interventions

  • DrugEfinopegdutide 20 mg/mL

    Drug page: Efinopegdutide

    Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg

    Also known as: MK-6024, HM12525A, JNJ-64565111

  • DrugSemaglutide 1.34 mg/mL

    Drug page: Semaglutide

    Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg

    Also known as: Ozempic®

06

What researchers measure

Primary outcomes

  1. Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks

    LFC was measured with liver images taken by MRI-PDFF and analyzed by BICR. Relative Reduction from Baseline to Week 24 = (Baseline - Week 24) / Baseline x 100%. Mean relative reduction from baseline in liver fat content is presented.

    Time frame: Baseline and up to ~24 Weeks

  2. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an adverse event is presented.

    Time frame: Up to ~29 weeks

  3. Percentage of Participants Who Discontinued Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to adverse event is presented.

    Time frame: Up to ~24 weeks

Secondary outcomes

  1. Mean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 Weeks

    LFC was measured by liver images taken by MRI-PDFF and analyzed by BICR. The absolute reduction from baseline to Week 24 = Baseline - Week 24. The mean absolute reduction from baseline in LFC after 24 weeks of treatment is presented.

    Time frame: Baseline and up to ~24 Weeks

  2. Mean Percent Change From Baseline in Body Weight After 24 Weeks

    Body weight in kilograms was measured using a standardized, digital scale. The mean percent change from baseline in body weight after 24 weeks is presented.

    Time frame: Baseline and up to ~24 weeks

  3. Mean Percent Change From Baseline in Total Cholesterol After 24 Weeks

    Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in total cholesterol. The mean percent change in total cholesterol is presented.

    Time frame: Baseline and up to ~24 weeks

  4. Mean Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) After 24 Weeks

    Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in non-HDL-C. The mean percent change in non-HDL-C is presented.

    Time frame: Baseline and up to ~24 weeks

  5. Mean Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 Weeks

    Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in HDL-C. Mean percent change in HDL-C is presented.

    Time frame: Baseline and up to ~24 weeks

  6. Mean Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 Weeks

    Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in LDL-C. The mean percent change in LDL-C is presented.

    Time frame: Baseline and up to ~24 weeks

  7. Mean Percent Change From Baseline in Triglycerides (TG) After 24 Weeks

    Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in triglycerides. The mean percent change in triglycerides is presented.

    Time frame: Baseline and up to ~24 weeks

  8. Mean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 Weeks

    Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in apoB. The mean percent change in apoB is presented.

    Time frame: Baseline and up to ~24 weeks

07

Results

Posted Nov 15, 2023

Participant flow

This study was conducted at 51 clinical sites in 16 countries.

Participant flow — Overall Study
MilestoneEfinopegdutideSemaglutide
Started7273
Completed6471
Not completed82
Withdrew: Lost to follow-up11
Withdrew: Physician decision10
Withdrew: Withdrawal by subject61

Outcome measures

PrimaryMean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks

LFC was measured with liver images taken by MRI-PDFF and analyzed by BICR. Relative Reduction from Baseline to Week 24 = (Baseline - Week 24) / Baseline x 100%. Mean relative reduction from baseline in liver fat content is presented.

Time frame:
Baseline and up to ~24 Weeks
Reported as:
Least squares mean · Percent Reduction
Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks
Percent ReductionEfinopegdutideSemaglutide
Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks72.7 (66.8 to 78.7)42.3 (36.5 to 48.1)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Mixed Models Analysis · p = <0.0001 · Difference in least squared means: 30.4 · 90% CI 22.1 to 38.7
PrimaryPercentage of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an adverse event is presented.

Time frame:
Up to ~29 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of ParticipantsEfinopegdutideSemaglutide
Percentage of Participants Who Experienced an Adverse Event (AE)88.972.6
Statistical analysis
  • Efinopegdutide vs Semaglutide · Difference in percentage: 16.3 · 95% CI 3.5 to 29.1
PrimaryPercentage of Participants Who Discontinued Study Intervention Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to adverse event is presented.

Time frame:
Up to ~24 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Intervention Due to an AE
Percentage of ParticipantsEfinopegdutideSemaglutide
Percentage of Participants Who Discontinued Study Intervention Due to an AE5.60
Statistical analysis
  • Efinopegdutide vs Semaglutide · Difference in percentage: 5.6 · 95% CI 0.4 to 13.5
SecondaryMean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 Weeks

LFC was measured by liver images taken by MRI-PDFF and analyzed by BICR. The absolute reduction from baseline to Week 24 = Baseline - Week 24. The mean absolute reduction from baseline in LFC after 24 weeks of treatment is presented.

Time frame:
Baseline and up to ~24 Weeks
Reported as:
Least squares mean · Percentage of liver fat
Mean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 Weeks
Percentage of liver fatEfinopegdutideSemaglutide
Mean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 Weeks14.9 (13.6 to 16.3)8.8 (7.5 to 10.1)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Mixed Models Analysis · p = <0.001 · Difference in least squared means: 6.1 · 90% CI 4.6 to 7.7
SecondaryMean Percent Change From Baseline in Body Weight After 24 Weeks

Body weight in kilograms was measured using a standardized, digital scale. The mean percent change from baseline in body weight after 24 weeks is presented.

Time frame:
Baseline and up to ~24 weeks
Reported as:
Least squares mean · Percent Change
Mean Percent Change From Baseline in Body Weight After 24 Weeks
Percent ChangeEfinopegdutideSemaglutide
Mean Percent Change From Baseline in Body Weight After 24 Weeks-8.5 (-9.5 to -7.5)-7.1 (-8.1 to -6.2)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Mixed Models Analysis · p = 0.085 · Difference in least squared means: -1.4 · 90% CI -2.7 to -0.1
SecondaryMean Percent Change From Baseline in Total Cholesterol After 24 Weeks

Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in total cholesterol. The mean percent change in total cholesterol is presented.

Time frame:
Baseline and up to ~24 weeks
Reported as:
Least squares mean · Percent Change
Mean Percent Change From Baseline in Total Cholesterol After 24 Weeks
Percent ChangeEfinopegdutideSemaglutide
Mean Percent Change From Baseline in Total Cholesterol After 24 Weeks-15.2 (-18.2 to -12.2)-8.0 (-11.0 to -5.0)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Difference in least squared means: -7.2 · 90% CI -11.2 to -3.1
SecondaryMean Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) After 24 Weeks

Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in non-HDL-C. The mean percent change in non-HDL-C is presented.

Time frame:
Baseline and up to ~24 weeks
Reported as:
Least squares mean · Percent Change
Mean Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) After 24 Weeks
Percent ChangeEfinopegdutideSemaglutide
Mean Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) After 24 Weeks-16.8 (-20.5 to -13.0)-11.0 (-14.8 to -7.3)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Difference in least squared means: -5.7 · 90% CI -10.9 to -0.6
SecondaryMean Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 Weeks

Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in HDL-C. Mean percent change in HDL-C is presented.

Time frame:
Baseline and up to ~24 weeks
Reported as:
Least squares mean · Percent Change
Mean Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 Weeks
Percent ChangeEfinopegdutideSemaglutide
Mean Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 Weeks-8.1 (-11.2 to -5.1)3.6 (0.6 to 6.6)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Difference in least squared means: -11.7 · 90% CI -15.8 to -7.7
SecondaryMean Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 Weeks

Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in LDL-C. The mean percent change in LDL-C is presented.

Time frame:
Baseline and up to ~24 weeks
Reported as:
Least squares mean · Percent Change
Mean Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 Weeks
Percent ChangeEfinopegdutideSemaglutide
Mean Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 Weeks-13.0 (-17.4 to -8.6)-6.9 (-11.3 to -2.6)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Difference in least squared means: -6.1 · 90% CI -12.0 to -0.1
SecondaryMean Percent Change From Baseline in Triglycerides (TG) After 24 Weeks

Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in triglycerides. The mean percent change in triglycerides is presented.

Time frame:
Baseline and up to ~24 weeks
Reported as:
Least squares mean · Percent Change
Mean Percent Change From Baseline in Triglycerides (TG) After 24 Weeks
Percent ChangeEfinopegdutideSemaglutide
Mean Percent Change From Baseline in Triglycerides (TG) After 24 Weeks-30.9 (-35.6 to -25.8)-23.3 (-28.5 to -17.7)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Difference in least squared means: -7.6 · 90% CI -14.3 to -0.9
SecondaryMean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 Weeks

Fasting blood samples were collected at baseline and after 24 weeks of treatment to assess mean percent change in apoB. The mean percent change in apoB is presented.

Time frame:
Baseline and up to ~24 weeks
Reported as:
Least squares mean · Percent Change
Mean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 Weeks
Percent ChangeEfinopegdutideSemaglutide
Mean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 Weeks-14.7 (-18.2 to -11.1)-9.2 (-12.8 to -5.7)
Statistical analysis
  • Efinopegdutide vs Semaglutide · Difference in least squared means: -5.4 · 90% CI -10.4 to -0.4

Adverse events

Collected over Death and adverse events up to ~29 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efinopegdutide0/72 (0%)1/72 (1.4%)57/72 (79.2%)
Semaglutide0/73 (0%)1/73 (1.4%)44/73 (60.3%)
Most frequent serious events
Most frequent serious events
EventEfinopegdutideSemaglutide
Calculus urinaryRenal and urinary disorders1/720/73
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/721/73
Most frequent other events
Showing 10 of 18
Most frequent other events
EventEfinopegdutideSemaglutide
NauseaGastrointestinal disorders20/7223/73
DiarrhoeaGastrointestinal disorders12/7213/73
ConstipationGastrointestinal disorders12/724/73
VomitingGastrointestinal disorders12/7211/73
Decreased appetiteMetabolism and nutrition disorders12/7211/73
COVID-19Infections and infestations8/7210/73
Abdominal painGastrointestinal disorders9/722/73
Abdominal pain upperGastrointestinal disorders7/721/73
DyspepsiaGastrointestinal disorders6/725/73
Gastrooesophageal reflux diseaseGastrointestinal disorders6/725/73

Baseline characteristics

Age, Continuous
Age, Continuous(Years)EfinopegdutideSemaglutideTotal
Mean48.0 ± 11.050.7 ± 10.949.4 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)EfinopegdutideSemaglutideTotal
Female394180
Male333265
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EfinopegdutideSemaglutideTotal
Hispanic or Latino252651
Not Hispanic or Latino464793
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)EfinopegdutideSemaglutideTotal
American Indian or Alaska Native325
Asian7714
Native Hawaiian or Other Pacific Islander000
Black or African American011
White6263125
More than one race000
Unknown or Not Reported000
Body Mass Index (BMI)
Body Mass Index (BMI)(Kg/M^2)EfinopegdutideSemaglutideTotal
Mean35.2 ± 5.733.5 ± 5.034.3 ± 5.4
Weight
Weight(kg)EfinopegdutideSemaglutideTotal
Mean100.2 ± 18.994.4 ± 18.997.3 ± 19.1
08

Study locations

69 sites
  • Catalina Research Institute, LLC ( Site 1939)
    Montclair, California 91763, United States
  • Sweet Hope Research Specialty, Inc ( Site 1902)
    Hialeah, Florida 33016, United States
  • Floridian Clinical Research, LLC ( Site 1950)
    Miami Lakes, Florida 33016, United States
  • Sensible Healthcare, LLC ( Site 1903)
    Ocoee, Florida 34761, United States
  • Lucas Research, Inc ( Site 1930)
    Morehead City, North Carolina 28557, United States
  • Texas Clinical Research Institute ( Site 1910)
    Arlington, Texas 76012, United States
  • Baylor College of Medicine-Advanced Liver Therapies ( Site 1960)
    Houston, Texas 77030, United States
  • American Research Corporation at Texas Liver Institute ( Site 1920)
    San Antonio, Texas 78215, United States
  • Clinical Trials of Texas, Inc. ( Site 1906)
    San Antonio, Texas 78229, United States
  • CIPREC-Laboratorio ( Site 0104)
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1119ACN, Argentina
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0101)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0105)
    Ciudad Autonoma de Buenos Aires, Caba C1425AGC, Argentina
  • IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 0107)
    Buenos Aires, C1012AAR, Argentina
  • Westmead Hospital-Gastroenterology & Hepatology ( Site 0204)
    Westmead, New South Wales 2145, Australia
  • Flinders Medical Centre-Hepatology and Liver Transplant Medicine ( Site 0201)
    Bedford Park, South Australia 5042, Australia
  • Heritage Medical Research Clinic ( Site 0302)
    Calgary, Alberta T2N 4Z6, Canada
  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital F-ENDOCRINOLOGY-DIABETOLOGY ( Site 0401)
    Dijon, Cote-d Or 21000, France
  • centre hospitalier lyon sud-Endocrinologie, Diabète et Nutrition ( Site 0402)
    Pierre-Bénite, Rhone 69310, France
  • Rambam Health Care Campus-Liver disease unit ( Site 0704)
    Haifa, 3109601, Israel
  • Carmel Hospital-Liver Unit ( Site 0705)
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center-Liver Unit ( Site 0703)
    Jerusalem, 9778419, Israel
  • Rabin Medical Center ( Site 0701)
    Petah-Tikva, 49100, Israel
  • Sheba Medical Center-The Liver Diseases Center ( Site 0700)
    Ramat Gan, 5262100, Israel
  • Sourasky Medical Center-Gastroenterology and Liver Disease ( Site 0702)
    Tel Aviv, 6423906, Israel
  • Policlinico Umberto I ( Site 0801)
    Roma, Lazio 00161, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0805)
    Milano, Lombardia 20122, Italy
  • Humanitas-Medicina interna ed Epatologia ( Site 0800)
    Rozzano, Lombardia 20089, Italy
  • Azienda Ospedaliero Universitaria ( Site 0803)
    Modena, 41125, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Medicine ( Site 0804)
    Verona, 37134, Italy
  • Soon Chun Hyang University Bucheon Hospital ( Site 1304)
    Bucheon, Kyonggi-do 14584, Korea, Republic of
  • Inha University Hospital-Gastroenterolgy/Hepatology ( Site 1303)
    Incheon, 22332, Korea, Republic of
  • Severance Hospital, Yonsei University Health System ( Site 1305)
    Seoul, 03722, Korea, Republic of
  • Samsung Medical Center-Gastroenterology/Internal Medicine ( Site 1302)
    Seoul, 06351, Korea, Republic of
  • Korea University Guro Hospital ( Site 1300)
    Seoul, 08308, Korea, Republic of
  • Medica Sur-Clinica de Enfermedades Digestivas y Obesidad ( Site 0908)
    Mexico City, Distrito Federal 14050, Mexico
  • Arké Estudios Clínicos S.A. de C.V.-Gastroenterology-Hepatology ( Site 0906)
    Mexico, Distrito Federal 06700, Mexico
  • Avix Investigación Clinica, S.C. ( Site 0907)
    Monterrey, Nuevo Leon 64710, Mexico
  • Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan (
    Merida, Yucatan 97130, Mexico
  • Centro de Investigación y Gastroenterología ( Site 0902)
    Cuauhtémoc, 06700, Mexico
  • Christchurch Hospital-Gastroenterology Research ( Site 1002)
    Christchurch, Canterbury 8011, New Zealand
  • Auckland City Hospital-Liver Research Unit ( Site 1003)
    Auckland, 1023, New Zealand
  • Middlemore Clinical Trials ( Site 1000)
    Auckland, 2025, New Zealand
  • Nasz Lekarz Przychodnie Medyczne ( Site 1105)
    Torun, Kujawsko-pomorskie 87-100, Poland
  • Centrum Medyczne Pratia Warszawa ( Site 1107)
    Warsaw, Mazowieckie 01-868, Poland
  • Clinical Medical Research ( Site 1101)
    Katowice, Slaskie 40-156, Poland
  • ID Clinic ( Site 1100)
    Mysowice, Slaskie 41-400, Poland
  • New Technologies of Medicine Clinic ( Site 1204)
    Dzerzhinskiy, Moskovskaya Oblast 140091, Russian Federation
  • Center targetnoy therapy ( Site 1203)
    Moscow, Moskva 125008, Russian Federation
  • Saint Petersburg City Polyclinic 117-endocrinology department ( Site 1201)
    Saint Petersburg, Sankt-Peterburg 194358, Russian Federation
  • Astarta Clinic ( Site 1202)
    Saint-Petersburg, Sankt-Peterburg 199226, Russian Federation
  • Hospital Universitario Virgen de la Victoria-UGC Endocrinologia y nutricion ( Site 1405)
    Malaga, Andalucia 29010, Spain
  • CHUS - Hospital Clinico Universitario ( Site 1403)
    Santiago de Compostela, La Coruna 15706, Spain
  • Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 1400)
    Barcelona, 08035, Spain
  • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA-Gastroenterologia y Hepatologia ( Site 1402)
    Madrid, 28222, Spain
  • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Unidad de Ensayos Clínicos de Aparato Digestivo ( Site 1404)
    Sevilla, 41013, Spain
  • NATIONAL CHENG-KUNG UNI. HOSP.-Liver Research team of National Cheng Kung University Hospital ( Site
    Tainan, 704, Taiwan
  • National Taiwan University Hospital ( Site 1501)
    Taipei, 10002, Taiwan
  • Chang Gung Medical Foundation-Linkou Branch-Division of hepatology, department of gastroenterology (
    Taoyuan, 333, Taiwan
  • Dokuz Eylül Üniversitesi-Endocrinology and Met. ( Site 1610)
    Balçova, Izmir 35330, Turkey
  • Ankara University Department of Hematology, Clinical Research Unit ( Site 1603)
    Ankara, 06100, Turkey
  • Hacettepe Universitesi-internal diseases ( Site 1602)
    Ankara, 06230, Turkey
  • Gazi Universitesi-gastroenterology ( Site 1605)
    Ankara, 06560, Turkey
  • Bezmialem Vakf Üniversitesi-Gastroenterology ( Site 1606)
    Istanbul, 34093, Turkey
  • Istanbul University Capa Campus-Gastroenterology ( Site 1604)
    Istanbul, 34093, Turkey
  • Ukrainian Research Institute of Therapy ( Site 1704)
    Kharkiv, Kharkivska Oblast 310039, Ukraine
  • L.T. Mala National Institute of Therapy of NAMS of Ukraine-Department of Aging Studies and Prevent
    Kharkiv, Kharkivska Oblast 61039, Ukraine
  • Poltova Oblast Clinical Hospital IM.M.V.Sklifosovskoho ( Site 1710)
    Poltava, Poltavska Oblast 36011, Ukraine
  • Communal Non-profit Enterprise "City Hospital #6" of Zaporizhzhia City Council-Therapy department (
    Zaporizhia, Zaporizka Oblast 69035, Ukraine
  • Adonis Plus-Outpatient department ( Site 1701)
    Kyiv, 02002, Ukraine
09

References and documents

Publications

  • Romero-Gomez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS; MK-6024 P001 Study Group. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023 Oct;79(4):888-897. doi: 10.1016/j.jhep.2023.05.013. Epub 2023 Jun 22. PubMed 37355043 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Oct 2022, 14 months.

Results were first posted in Nov 2023, 1 year after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 14 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jun 30, 2021
StartActual
Aug 4, 2021
Primary completionActual
Oct 19, 2022
CompletionActual
Oct 19, 2022
Results first posted
Nov 15, 2023
Last update
Nov 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04944992
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
Aug 4, 2021
Primary completion
Oct 19, 2022
Completion
Oct 19, 2022
Results posted
Nov 15, 2023
Last update
Nov 15, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion